Search results
Added:
9 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more
Added:
10 months ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists.
View more
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
Added:
11 months ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 year ago
AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating…
View more
Added:
1 year ago
HFSA 2024 - We are joined by Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) to discuss the findings from HuMAIN HFpEF, a phase 2A randomized, parallel-group, placebo-controlled study of HU6 in patients with obesity and heart failure with preserved ejection fraction (HFpEF).Interview Questions:What is the reasoning behind this study?Could you tell us about the mechanism…
View more
AHA 24: The SELECT Trial
Added:
1 year ago
Video
Added:
11 months ago
ECO 2025 - Three-year findings of tirzepatide treatment, a GIP/GLP-1 agonist, for patients with prediabetes observed stable weight loss results and suggests that tirzepatide is a viable option for patients with indication. The study also observed the total weight loss patients may obtain can be predicted within the first month of treatment with tirzepatide.Prof Luca Busetto (Padova University…
View more
Added:
1 year ago
In this third session of Advancements in Obesity Management (AOM) 2024, the panel explore the biological,environmental,psychologicaland social factors contributing to obesity.
View more
Added:
1 year ago
In the final session of Advancements in Obesity Management (AOM) 2024, the panel discuss practical considerations in utilising new pharmacological therapies for treating obesity and cover the extensive development pipeline. The current understanding of clinical outcome data and patient referral criteria are also discussed for surgical approaches.
View more